Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye. 2011;25(6):661-672.
Antonopoulos C, Stem M, Comer GM. Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab. Clin Ophthalmol. 2011; 5:1659-1662.
Sophie R, Akhtar A, Sepah YJ, et al. Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases. Biol Ther. 2012; 2:3.
Semeraro F, Morescalchi F, Duse S, et al. Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. Curr Drug Metab. 2015;16(7):572-584.
Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98(12):1636-1641.
Murinello S, Mullins RF, Lotery AJ, Perry VH, Teeling JL. Fcγ Receptor Upregulation Is Associated With Immune Complex Inflammation in the Mouse Retina and Early Age-Related Macular DegenerationFcγ Receptors and ADM. Investigative Ophthalmology & Visual Science. 2014;55(1):247-258.
Semeraro F, Morescalchi F, Duse S, et al. Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. Curr Drug Metab. 2015;16(7):572-584.
Murinello S, Mullins RF, Lotery AJ, Perry VH, Teeling JL. Fcγ Receptor Upregulation Is Associated With Immune Complex Inflammation in the Mouse Retina and Early Age-Related Macular DegenerationFcγ Receptors and ADM. Investigative Ophthalmology & Visual Science. 2014;55(1):247-258.
Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis. 2009; 15:2803-2812.
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715-725.
Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98(12):1636-1641.
Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7(1):171-181.
van Wijngaarden P, Qureshi SH. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Clin Exp Optom. 2008;91(5):427-437.
Deissler HL, Lang GK, Lang GE. Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells. Graefes Arch Clin Exp Ophthalmol. 2015;253(6):885-894.
Li X, Lee C, Tang Z, et al. VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr. 2009;3(4):322-327.
Zentilin L, Puligadda U, Lionetti V, et al. Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction. FASEB J. 2010;24(5):1467-1478.
Sheibani N. Placental growth factor inhibition for choroidal neovascularization. J Ophthalmic Vis Res. 2013;8(1):1-3.
Vandewynckel YP, Laukens D, Devisscher L, et al. Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma. BMC Cancer. 2016; 16:9.
Yang J, Wang X, Fuh G, et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm. 2014;11(10):3421-3430.
Semeraro F, Morescalchi F, Duse S, et al. Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. Curr Drug Metab. 2015;16(7):572-584.
Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012; 6:1175-1186.
Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154(4):682-686 e682. http://dx.doi.org/10.1016/j.ajo.2012.03.047
Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous Levels of Bevacizumab and Vascular Endothelial Growth Factor-A in Patients with Choroidal Neovascularization. Ophthalmology. 2008;115(10):1750-1755.e1751.
Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847-1858.
Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847-1858.
Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65(3):550-563.
Van Lookeren Campagne M, LeCouter J, Yaspan BL, Ye W. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 2014;232(2):151-164.
Ozaki E, Campbell M, Kiang AS, et al. Inflammation in age-related macular degeneration. Adv Exp Med Biol. 2014;801:229-235.
Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis. 1999;5:34.
Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic Macular Edema: Pathogenesis and Treatment. Surv Ophthalmol. 2008;54(1):1-32.
Gundogan FC, Yolcu U, Akay F, et al. Diabetic Macular Edema. Pakistan Journal of Medical Sciences. 2016;32(2):505-510.
Abdel Rasol H, Azab A. Vitreous, aqueous, and serum levels of vascular endothelial growth factor and angiopoietin-2 in patients with proliferative diabetic retinopathy and diabetic macular edema. Middle East Afr J Ophthalmol. 2007;14(1):3-6.
Owen LA, Hartnett ME. Soluble Mediators of Diabetic Macular Edema: The Diagnostic Role of Aqueous VEGF and Cytokine Levels in Diabetic Macular Edema. Current diabetes reports. 2013;13(4):476-480.
Aggarwal RS, Mishra VV, Aggarwal SV. Oral contraceptive pills: A risk factor for retinal vascular occlusion in in-vitro fertilization patients. J Hum Reprod Sci. 2013;6(1):79-81.
Shchuko AG, Zlobin IV, Iureva TN, et al. Intraocular cytokines in retinal vein occlusion and its relation to the efficiency of anti-vascular endothelial growth factor therapy. Indian J Ophthalmol. 2015;63(12):905-911.
Deobhakta A, Chang LK. Inflammation in Retinal Vein Occlusion. International Journal of Inflammation. 2013; 2013:6.
Neelam K, Cheung CM, Ohno-Matsui K, Lai TY, Wong TY. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31(5):495-525.
Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85(4):425-430.
Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120(3):338-346.
Kurt MM, Cekic O, Akpolat C, Elcioglu M. Effects of intravitreal ranibizumab and bevacizumab on the retinal vessel size in diabetic macular edema. Retina. 2018;38(6):1120-1126.
Hillier RJ, Ojaimi E, Wong DT, et al. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. JAMA Ophthalmol. 2018;136(4):382-388.
Sakamoto S, Takahashi H, Tan X, et al. Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy. Br J Ophthalmol. 2018;102(4):448.
Lazzeri S, Orlandi P, Piaggi P, et al. IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics. 2016;17(1):35-39.
Hillier RJ, Ojaimi E, Wong DT, et al. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. JAMA Ophthalmol. 2018;136(4):382-388.
Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21(5):416-434.
Parodi MB, Iacono P, Menchini F, et al. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. Acta Ophthalmol. 2013;91(3):267-273.
Shimada H, Kawamura A, Mori R, Yuzawa M. Clinicopathological findings of retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2007;245(2):295-300.
Marcus DM, Singh H, Lott MN, Singh J, Marcus MD. Intravitreal ranibizumab for polypoidal choroidal vasculopathy in non-Asian patients. Retina. 2013;33(1):35-47.
Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453-1464.
Houle JM, Strong HA. Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin. Retina. 2002;22(6):691-697.
EMA Visudyne, Summary of product characteristics. Last updated: 29-Aug-2018.
Visudyne Prescribing Information. Last updated: April-2016.
Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(4):623 e621.
Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046-1056.
Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181-2192.
Wykoff CC, Brown DM, Croft DE, Wong TP. Two year SAVE outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. Ophthalmology. 2013;120(9):1945-1946 e1941.
NCT01025232. A study of intravitreal injections of 2.0 mg ranibizumab in subjects with chronic fluid on oct post multiple injections with ranibizumab (Super-dose Anti-VEgf SAVE Trial) (SAVE). Clinicaltrials.gov. Last updated: 02-Jan-2017.
Fung AT, Kumar N, Vance SK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye (Lond). 2012;26(9):1181-1187.
Sepah YJ, Sadiq MA, Boyer D, et al. Twenty-four month outcomes of the ranibizumab for edema of the macula in diabetes - protocol 3 with high dose (READ-3) study. Ophthalmology. 2016;123(12):2581-2587.
Ferrone PJ, Jonisch J. Comparison of ranibizumab 0.5 mg versus 1.0 mg for the treatment of patients with clinically significant diabetic macular edema: A randomized, clinical trial. Ophthalmic Surg Lasers Imaging Retina. 2016;47(6):536-543.
Marcus DM, Singh H, Fechter CM, Chamberlain DP. High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population. Eye (Lond). 2015;29(11):1427-1437.
NCT01884597. Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2). Cli icaltrials.gov. Last updated: 9th-Oct-2017.
Barthelmes D, Walton RJ, Arnold JJ, et al. Intravitreal therapy in bilateral neovascular age-related macular degeneration. Ophthalmology. 2014;121(10):2073-2074.
Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol. 2012;96(5):688-693.
Zarranz-Ventura J, Liew G, Johnston RL, et al. The neovascular age-related macular degeneration database: Report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014;121(10):1966-1975.
Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117(4):429-441.
Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157(1):9-25. e12.
Davis RP, Schefler AC, Murray TG. Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration. Clin Ophthalmol. 2010; 4:703-707.
Shah M, Amoaku WM. Same-day consecutive bilateral intravitreal injections of ranibizumab for the treatment of bilateral active choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol. 2012;90(6): e491-e493.
Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-2405. http://dx.doi.org/10.2337/dc10-0493
Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121(5):1045-1053. http://dx.doi.org/10.1016/j.ophtha.2013.11.041
Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625. http://dx.doi.org/10.1016/j.ophtha.2011.01.031
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801. http://dx.doi.org/10.1016/j.ophtha.2011.12.039
Brown DM, Nguyen QD, Marcus DM, et al. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-2022. http://dx.doi.org/10.1016/j.ophtha.2013.02.034
Ip MS, Domalpally A, Hopkins J, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology. 2012;130(9):1145-1152. http://dx.doi.org/10.1001/archophthalmol.2012.1043
Ishibashi T, Li X, Koh A, et al. The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema. Ophthalmology. 2015;122(7):1402-1415. http://dx.doi.org/10.1016/j.ophtha.2015.02.006
Prunte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100(6):787-795. http://dx.doi.org/10.1136/bjophthalmol-2015-307249
Li X, Dai H, Li X, et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefes Arch Clin Exp Ophthalmol. 2019;257(3):529-541. http://dx.doi.org/10.1007/s00417-018-04213-x
Elman MJ, Qin H, Aiello LP, et al. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: Three-Year Randomized Trial Results. Ophthalmology. 2012;119(11):2312-2318. http://dx.doi.org/10.1016/j.ophtha.2012.08.022
US National Institutes of Health. ClinicalTrials.gov. Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS). NCT01318941.
Brand C, Mitchell P, Holz FG, et al. Abstract 29: Baseline characteristics of patients enrolled in the real-world LUMINOUS study: data from the final analysis. 17th ESASO Retina Academy; June 29-July 1, 2017; Berlin, Germany. Ophthalmic Res. 2017;58 (Suppl. 1):1-20.
Mitchell P, Ziemssen F, Sheidow T, Parikh S, Macfadden W. Visual acuity outcomes in DME patients treated with ranibizumab in a real-life setting: results from the final analysis of the LUMINOUS study. Presented at 17th EURETINA Congress; September 7‒10, 2017; Barcelona, Spain.
Mitchell P, Parikh S and Macfadden W. Effectiveness of ranibizumab for the treatment of patients with diabetic macular edema in a real-world setting: 1- and 2-year results from the LUMINOUS™ study. Invest Ophthalmol Vis Sci. 2018;59 (9):3617. https://iovs.arvojournals.org/article.aspx?articleid=2693483&resultClick=1
Fourmaux E, Lecleire-Collet A, Dot C, et al. Real-world outcomes with ranibizumab 0.5 mg in treatment-naïve French patients with visual impairment due to diabetic macular edema: 12-month results from the ETOILE study. Invest Ophthalmol Vis Sci. 2017;58(8):4625-4625.
Stefanickova J, Cunha-Vaz J, Ulbig M, et al. A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS). Acta Ophthalmologica. 2018;96(8):e942-e949.
Massin P, Creuzot-Garcher C, Kodjikian L, et al. Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study. Ophthalmic Res. 2019;10.1159/000497406:1-10.
Parodi MB, Iacono P, Menchini F, et al. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. Acta Ophthalmol. 2013;91(3):267-273.
Shin JY, Yu HG. Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients. Retina. 2014;34(12):2359-2366.
Konstantinidis L, Mameletzi E, Mantel I, et al. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol. 2009;247(9):1165-1171.
Kim JH, Chang YS, Kim JW, Kim CG, Lee DW. Recurrence in patients with type 3 neovascularization (retinal angiomatous proliferation) after intravitreal ranibizumab. Retina. 2017;37(8):1508-1515.
Parodi MB, Donati S, Semeraro F, et al. Intravitreal Anti-Vascular Endothelial Growth Factor Drugs for Retinal Angiomatous Proliferation in Real-Life Practice. J Ocul Pharmacol Ther. 2017;33(2):123-127.
Hufendiek K, Hufendiek K, Panagakis G, Helbig H, Gamulescu MA. Visual and morphological outcomes of bevacizumab (Avastin(R)) versus ranibizumab (Lucentis(R)) treatment for retinal angiomatous proliferation. Int Ophthalmol. 2012;32(3):259-268.
Park YG, Roh YJ. One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages. BMC Ophthalmol. 2015; 15:182.
Cho HJ, Hwang HJ, Kim HS, et al. Intravitreal aflibercept and ranibizumab injections for type 3 neovascularization. Retina. 2018;38(11):2150-2158.
Malamos P, Tservakis I, Kanakis M, et al. Long-Term Results of Combination Treatment with Single-Dose Ranibizumab plus Photodynamic Therapy for Retinal Angiomatous Proliferation. Ophthalmologica. 2018;240(4):213-221.
Xiaoxin Li et al. Ranibizumab 0.5 mg in patients with polypoidal choroidal vasculopathy: results from the DRAGON study. Presented at AAO Congress, October 15-18, 2016, Chicago, USA.
Miyamoto N, Mandai M, Oishi A, et al. Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. Br J Ophthalmol. 2018;10.1136/bjophthalmol-2018-312419. http://dx.doi.org/10.1136/bjophthalmol-2018-312419
Marcus DM, Singh H, Lott MN, Singh J, Marcus MD. Intravitreal ranibizumab for polypoidal choroidal vasculopathy in non-Asian patients. Retina. 2013;33(1):35-47. http://dx.doi.org/10.1097/IAE.0b013e3182618be0
Koh AHC, Parikh S. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: 24-month results from the EVEREST II study. Invest Ophthalmol Vis Sci. 2018;59(9):831. https://iovs.arvojournals.org/article.aspx?articleid=2693616&resultClick=1
Brand C, Parikh S and Macfadden W. Baseline characteristics of the 30,000 patients enrolled in LUMINOUS™, a real-world study with ranibizumab. Invest Ophthalmol Vis Sci. 2018;59(9):3902.
Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453-1464.
Koh A, Lai TYY, Takahashi K, et al. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2017;135(11):1206-1213.
Koh AHC, Parikh S. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: 24-month results from the EVEREST II study. Invest Ophthalmol Vis Sci. 2018;59(9):831.
Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012;119(5):1001-1010.
Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012;119(5):992-1000.
Antoszyk AN, Tuomi L, Chung CY, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145(5):862-874.
Weingessel B, Mihaltz K, Vecsei-Marlovits PV. Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration. Wien Klin Wochenschr. 2016;128(15-16):560-565.
L.Hudson H. Radical: 24-month results of a phase II exploratory randomized clinical trial of reduced fluence vPDT anti VEGF dexamethasone in AMD; ARVO annual meeting abstract; April 2011.
Bandello F, Staurenghi G, Ricci F, et al. Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study. Br J Ophthalmol. 2019;10.1136/bjophthalmol-2019-313907.
Novartis clinical trial results website. Available at:
Pagliarini S, Beatty S, Lipkova B, et al. A 2-year, Phase IV, multicentre, observational study of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration in routine clinical practice: The EPICOHORT study. J Ophthalmol. 2014; 2014:857148.
Zarranz-Ventura J, Liew G, Johnston RL, et al. The neovascular age-related macular degeneration database: Report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014;121(10):1966-1975.
Barthelmes D, Walton RJ, Arnold JJ, et al. Intravitreal therapy in bilateral neovascular age-related macular degeneration. Ophthalmology. 2014;121(10):2073-2074.
Bandello F, Staurenghi G, Ricci F, et al. Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study. Br J Ophthalmol. 2019;10.1136/bjophthalmol-2019-313907.
Novartis clinical trial results website. Available at:
Pagliarini S, Beatty S, Lipkova B, et al. A 2-year, Phase IV, multicentre, observational study of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration in routine clinical practice: The EPICOHORT study. J Ophthalmol. 2014; 2014:857148.
Zarranz-Ventura J, Liew G, Johnston RL, et al. The neovascular age-related macular degeneration database: Report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014;121(10):1966-1975.
Barthelmes D, Walton RJ, Arnold JJ, et al. Intravitreal therapy in bilateral neovascular age-related macular degeneration. Ophthalmology. 2014;121(10):2073-2074.
Retinoblastoma Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. 2002.
Apte RS, Harbour JW. Inhibiting angiogenesis in retinoblastoma. Ophthalmic Res. 2007;39(4):188-190.
Kvanta A, Steen B, Seregard S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 1996;63(5):511-518.
Retinoblastoma Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. 2002.
Apte RS, Harbour JW. Inhibiting angiogenesis in retinoblastoma. Ophthalmic Res. 2007;39(4):188-190.
Kvanta A, Steen B, Seregard S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 1996;63(5):511-518.
Stathopoulos C, Gaillard MC, Moulin A, et al. Intravitreal anti-vascular endothelial growth factor for the management of neovascularization in retinoblastoma after intravenous and/or intraarterial chemotherapy: Long-term outcomes in a series of 35 eyes. Retina. 2018;10.1097/iae.0000000000002339.
Penedones A, Mendes D, Alves C, Batel Marques F. Safety monitoring of ophthalmic biologics: a systematic review of pre- and postmarketing safety data. J Ocul Pharmacol Ther. 2014;30(9):729-751. http://dx.doi.org/10.1089/jop.2013.0206
Mamalis N, Edelhauser HF, Dawson DG, et al. Toxic anterior segment syndrome. J Cataract Refract Surg. 2006;32(2):324-333.
Mamalis N, Edelhauser HF, Dawson DG, et al. Toxic anterior segment syndrome. J Cataract Refract Surg. 2006;32(2):324-333.
Novosad BD, Callegan MC. Severe bacterial endophthalmitis: towards improving clinical outcomes. Expert Rev Ophthalmol. 2010;5(5):689-698.
Ta CN. Minimizing the risk of endophthalmitis following intravitreous injections. Retina. 2004;24(5):699-705
Agrawal S, Joshi M, Christoforidis JB. Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. Mediators Inflamm. 2013; 2013:6.
Agrawal S, Joshi M, Christoforidis JB. Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. Mediators Inflamm. 2013; 2013:6.
Berger AB SS. Severe intraocular inflammation/endophthalmitis following off-label treatment with intravitreal bevacizumab. Ophthalmology Scientific Update, Faculty of Medicine, University of Toronto. 2009.
Georgopoulos M, Polak K, Prager F, Prunte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93(4):457-462.
Van Wijngaarden P, Qureshi SH. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Clin Exp Optom. 2008;91(5):427-437.
Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220-233.
Amoaku WM. Ranibizumab: a medical treatment that requires surgical administration. Eye (Lond). 2011;25(4):399-401.
Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116(9):1731-1739. http://dx.doi.org/10.1016/j.ophtha.2009.05.024
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65 e55.
Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-2405.
Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594-1602.
Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041-2049.
Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
Silva R, Axer-Siegel R, Eldem B, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):130-139.
Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181-2192.
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201.
Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121(5):1045-1053.
Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121(3):682-692 e682.
Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122(2):375-381.
Ishibashi T, Li X, Koh A, et al. The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema. Ophthalmology. 2015;122(7):1402-1415.
Prunte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100(6):787-795.
Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016;123(6):1351-1359.
Gross JG, Glassman AR, Liu D, et al. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2018;136(10):1138-1148.
Silva R, Berta A, Larsen M, et al. Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study. Ophthalmology. 2018;125(1):57-65.
Mitchell P, Parikh S, Macfadden W. Effectiveness of ranibizumab for the treatment of patients with diabetic macular edema in a real-world setting: 1- and 2-year results from the LUMINOUS™ study. Invest Ophthalmol Vis Sci. 2018;59(9):3617.
Sharma S, Parikh S, Macfadden W. Ranibizumab treatment for nAMD in clinical practice: outcomes from the LUMINOUS™ study. Poster presented at ARVO annual meeting; April 29-May 3, 2018; Honolulu, Hawaii, USA.
Sharma S, Johnson D, Abouammoh M, Hollands S, Brissette A. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol. 2012;47(3):275-279.
Casparis H, Wolfensberger TJ, Becker M, et al. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. Retina. 2014;34(1):12-17.
Pagliarini S, Beatty S, Lipkova B, et al. A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study. J Ophthalmol. 2014; 2014:857148.
Tabandeh H, Boscia F, Sborgia A, et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina. 2014;34(1):18-23.
Bhavsar AR, Sandler DR. Eliminating antibiotic prophylaxis for intravitreal injections: a consecutive series of 18,839 injections by a single surgeon. Retina. 2015;35(4):783-788.
Gregori NZ, Flynn HW, Jr., Schwartz SG, et al. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment. Ophthalmic Surg Lasers Imaging Retina. 2015;46(6):643-648.
Jonna G, Roth BD, Fine FH, et al. Inferior intravitreal injection site associated with a higher incidence of post - injection endophthalmitis. Guoji Yanke Zazhi(Int Eye Sci). 2015;15(5):750-754.
Meredith TA, McCannel CA, Barr C, et al. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2015;122(4):817-821.
Buckle M, Donachie PH, Johnston RL. Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK. Br J Ophthalmol. 2016;100(2):240-245.
Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36(8):1418-1431.
Rayess N, Rahimy E, Storey P, et al. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept. Am J Ophthalmol. 2016; 165:88-93.
Souied EH, Dugel PU, Ferreira A, et al. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Ophthalmic Epidemiol. 2016;23(2):71-79.
Daien V, Nguyen V, Essex RW, et al. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. Ophthalmology. 2017; 10.1016/j.ophtha.2017.07.005.
Forooghian F, Albiani DA, Kirker AW, Merkur AB. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept. Can J Ophthalmol. 2017;52(6):616-619.
Marciano I, Cutroneo PM, Giardina C, et al. Safety profile of intravitreal anti-VEGF drugs: An analysis of the Italian spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2017; 26:382-383.
Baudin F, Benzenine E, Mariet AS, et al. Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France. JAMA Ophthalmol. 2018;136(12):1352-1358.
Bavinger JC, Yu Y, VanderBeek BL. Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab. Retina. 2018;10.1097/iae.0000000000002351.
Borkar DS, Obeid A, Su DC, et al. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2018; 194:1-6.
Kiss S, Dugel PU, Khanani AM, et al. Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. Clin Ophthalmol. 2018; 12:1625-1635.
Munro M, Williams GR, Ells A, et al. Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections. Br J Ophthalmol. 2018;102(9):1254-1258.
Rayess N, Obeid A, Storey PP, et al. Long-term visual outcomes and clinical features after anti-vascular endothelial growth factor injection-related endophthalmitis. Retina. 2018;10.1097/iae.0000000000002300.
Storey PP, Tauqeer Z, Yonekawa Y, et al. The Impact of Prefilled Syringes on Endophthalmitis following Intravitreal Injection of Ranibizumab. Am J Ophthalmol. 2019; 199:200-208. 2018; 10.1016/j.ajo.2018.11.023.
Xu K, Chin EK, Bennett SR, et al. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes. Ophthalmology. 2018;125(8):1279-1286.
Zafar S, Hamid A, Bin Mahmood SU, Burq MA, Maqsood N. Incidence of endophthalmitis after intravitreal injections at a tertiary care hospital. Can J Ophthalmol. 2018;53(2):94-97.
Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148(5):647-656.
Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis. 2009; 15:2803-2812.
Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788-1795.
Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol. 2003;21(18):3542; author reply 3543.
Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2012;90(1):e25-30.
Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97(4):454-459.
Zarbin MA, Dunger-Baldauf C, Haskova Z, et al. Vascular safety of ranibizumab in patients with diabetic macular edema: A pooled analysis of patient-level data from randomized clinical trials. JAMA Ophthalmology. 2017;135(5):424-431.
Zarbin MA, Francom S, Grzeschik S, et al. Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis. Ophthalmology Retina. 2018;2(11):1087-1096.
Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65 e55.
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181-2192.
Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012;119(5):992-1000.
Heier JS, Brown DM, Chong V, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology. 2012;119(12):2537-2548.
Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258-1267.
Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013;120(11):2300-2309.
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594-1602.
Blumenthal DK, Garrison JC. Pharmacodynamics: Molecular Mechanisms of Drug Action. Goodman &amp; Gilman's: The Pharmacological Basis of Therapeutics, 12e. 2011,
Biaggioni I, Robertson D. Adrenoceptor Agonists &amp; Sympathomimetic Drugs. Basic &amp; Clinical Pharmacology, 13e. 2015,
von Zastrow M. Drug Receptors &amp; Pharmacodynamics. Basic &amp; Clinical Pharmacology, 13e. 2015,
Jutley G, Shona OA, Leen RC, et al. Response to ranibizumab following tachyphylaxis to bevacizumab in a patient with radiation maculopathy following stereotactic fractionated radiotherapy for optic nerve meningioma. Arch Ophthalmol. 2012;130(11):1466-1470.
Forooghian F, Chew EY, Meyerle CB, Cukras C, Wong WT. Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmol. 2011;89(2): e206-207.
Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008;115(12):2199-2205.
Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21-23.
Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008;115(12):2199-2205.
Jutley G, Shona OA, Leen RC, et al. Response to ranibizumab following tachyphylaxis to bevacizumab in a patient with radiation maculopathy following stereotactic fractionated radiotherapy for optic nerve meningioma. Arch Ophthalmol. 2012;130(11):1466-1470.
Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? British Journal of Ophthalmology. 2012;96(1):1.
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65 e55.
Doguizi S, Ozdek S, Yuksel S. Tachyphylaxis during ranibizumab treatment of exudative age-related macular degeneration. Int J Ophthalmol. 2015;8(4):846-848.
Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21-23.
Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(7):3115-3120.
Mori R, Tanaka K, Yuzawa M. Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity. Medicine. 2018;97(25):e11188-e11188.
Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol. 2010; 4:809-816.
Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of Macular Edema With Branch Retinal Vein Occlusion and Intraocular Levels of Vascular Endothelial Growth Factor and Interleukin-6. Am J Ophthalmol. 2005;140(2): 256.e251-256.e257.
Fujikawa M, Sawada O, Miyake T, et al. Correlation between vascular endothelial growth factor and nonperfused areas in macular edema secondary to branch retinal vein occlusion. Clin Ophthalmol. 2013; 7:1497-1501.
Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041-2049.
Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594-1602.
Thach AB, Yau L, Hoang C, Tuomi L. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology. 2014;121(5):1059-1066.
Larsen M, Waldstein SM, Priglinger S, et al. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study. Ophthalmol Retina. 2018;2(2):134-142.
Tadayoni R, Waldstein SM, Boscia F, et al. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study. Ophthalmology. 2017;10.1016/j.ophtha.2017.06.027.
Ma Z, Zhu L, Weisberger A, Cheng Y, Liu C. Ranibizumab 0.5 mg in Asian patients with visual impairment due to macular edema secondary to central retinal vein occlusion: results from the 12-month CAMELLIA study. Invest Ophthalmol Vis Sci. 2017;58(8):1543-1543.
Wei w, Zhu L, Weisberger A, Cheng Y, Liu C. Efficacy and safety of ranibizumab 0.5 mg in Asian patients with visual impairment due to macular edema secondary to branch retinal vein occlusion: results from the 12-month BLOSSOM study. Invest Ophthalmol Vis Sci. 2017;58(8):4619-4619.
Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Long-term Follow-up in the HORIZON Trial. Ophthalmology. 2012;119(4):802-809.
Campochiaro PA, Sophie R, Pearlman J, et al. Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab: The RETAIN Study. Ophthalmology. 2014;121(1):209-219.
Campochiaro PA, Wykoff CC, Singer M, et al. Monthly Versus As-Needed Ranibizumab Injections in Patients with Retinal Vein Occlusion: The SHORE Study. Ophthalmology. 2014;121(12):2432-2442.
Hattenbach LO, Feltgen N, Bertelmann T, et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol. 2018;96(1): e10-e18.
Hoerauf H, Feltgen N, Weiss C, et al. Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. Am J Ophthalmol. 2016; 169:258-267.
Carneiro AM, Silva RM, Veludo MJ, et al. Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia. Ophthalmologica. 2011;225(2):81-88.
Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of Choroidal Neovascularization in Young Patients. Ophthalmology. 1996;103(8):1241-1244.
Carneiro AM, Silva RM, Veludo MJ, et al. Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia. Ophthalmologica. 2011;225(2):81-88.
Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002;64(1):162-169.
Munk MR, Ruckert R, Zinkernagel M, Ebneter A, Wolf S. The role of anti-VEGF agents in myopic choroidal neovascularization: current standards and future outlook. Expert Opin Biol Ther. 2016;16(4):477-487.
Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157(1):9-25. e12.
Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120(9):1944-1945.e1941.
Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121(3):682-692.e682.
Chen Y, Sharma T, Li X, et al. Ranibizumab versus verteporfin photodynamic therapy in asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study. Retina. 2018;10.1097/iae.0000000000002292.
Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65. e55.
Chen Y, Sharma T, Li X, et al. Ranibizumab versus verteporfin photodynamic therapy in asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study. Retina. 2018;10.1097/iae.0000000000002292.
Li S, Ding X, Sun L, et al. Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study. Clin Exp Ophthalmol. 2019;47(2):250-258.
Lai TYY, Staurenghi G, Lanzetta P, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: Twelve-Month Results of the MINERVA Study. Retina. 2018;38(8):1464-1477.
Mimoun G, Ebran JM, Grenet T, et al. Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France. Graefes Arch Clin Exp Ophthalmol. 2017;255(8):1651-1660.
Ladas DS, Koutsandrea C, Kotsolis AI, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to angiod streaks. Comparison of the 12 and 24-month results of treatment in treatment-naive eyes. Eur Rev Med Pharmacol Sci. 2016;20(13):2779-2785.
Carreno E, Moutray T, Fotis K, et al. Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes. Br J Ophthalmol. 2016;100(9):1221-1226.
Battaglia Parodi M, Munk MR, Iacono P, Bandello F. Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease. British Journal of Ophthalmology. 2015;99(9):1268.
Cao XS, Peng XY, You QS, Zhang YP, Jonas JB. Subfoveal choroidal thickness change after intravitreal ranibizumab for idiopathic choroidal neovascularization. Retina. 2014;34(8):1554-1559.
Artunay O, Yuzbasioglu E, Rasier R, et al. Combination treatment with intravitreal injection of ranibizumab and reduced fluence photodynamic therapy for choroidal neovascularization secondary to angioid streaks: preliminary clinical results of 12-month follow-up. Retina. 2011;31(7):1279-1286.
Finger RP, Charbel Issa P, Hendig D, Scholl HP, Holz FG. Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: a one-year prospective study. Am J Ophthalmol. 2011;152(4):695-703.
Ladas ID, Kotsolis AI, Ladas DS, et al. Intravitreal ranibizumab treatment of macular choroidal neovascularization secondary to angioid streaks: one-year results of a prospective study. Retina. 2010;30(8):1185-1189.
Carneiro AM, Silva RM, Veludo MJ, et al. Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia. Ophthalmologica. 2011;225(2):81-88.
Tilleul J, Mimoun G, Querques G, et al. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks: Four-Year Follow-up. Retina. 2016;36(3):483-491.
Altun A, Kurna SA, Olcaysu OO, et al. Success of ranibizumab in central serous chorioretinopathy resistant to bevacizumab. J Ocul Pharmacol Ther. 2014;30(10):842-846.
Kang HM, Koh HJ. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization. Am J Ophthalmol. 2013;155(4):713-719, 719.e711.
Shah M, Amoaku WM. Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks. Eye (Lond). 2012;26(9):1194-1198.
Rouvas A, Petrou P, Douvali M, et al. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina. 2011;31(5):871-879.
Shi X, Wei W, Zhang C. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness. Chin Med J (Engl). 2014;127(12):2279-2285.
Ozdemir O, Erol MK. Morphologic changes and visual outcomes in resolved central serous chorioretinopathy treated with ranibizumab. Cutan Ocul Toxicol. 2014;33(2):122-126.
Erol MK, Ozdemir O, Coban DT, Ceran BB, Bulut M. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity. Semin Ophthalmol. 2014;29(2):108-113.
Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. Eur J Ophthalmol. 2010;20(5):955-958.
Dolz-Marco R, Gallego-Pinazo R, Pardo D, et al.  Adult Onset Foveomacular Vitelliform Dystrophy and Ranibizumab. Invest Ophthalmol Vis Sci. 2011;52(14):5013.
Madhusudhan S, Heimann H, Beare N, and Harding S. Intravitreal Ranibizumab Therapy In Mactel. Invest Ophthalmol Vis Sci. 2011;52(14):4529.
Tian D, Yang J. Intravitreal injections of ranibizumab in treatment of idiopathic choroidal neovascularization. Int J Clin Exp Med. 2016;9(2):3780-3784.
Yumusak E, Gokcinar NB, Ornek K. Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy. Medicine (Baltimore). 2018;97(43): e12885.
Zehetner C, Haas G, Treiblmayr B, Kieselbach GF, Kralinger MT. Reduced-fluence photodynamic therapy combined with ranibizumab for nonproliferative macular telangiectasia type 2. Ophthalmologica. 2013;229(4):195-202.
Mimoun G, Caillaux V, Querques G, et al. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results. Retina. 2013;33(3):513-521.
Gallego-Pinazo R, Dolz-Marco R, Pardo-Lopez D, Arevalo JF, Diaz-Llopis M. Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy. Graefes Arch Clin Exp Ophthalmol. 2011;249(3):455-458.
Tranos PG, Wickremasinghe SS, Stangos NT, et al. Macular edema. Survey of Ophthalmology. 2004;49(5):470-490.
Scholl S, Augustin A, Loewenstein A, Rizzo S, Kuppermann BD. General Pathophysiology of Macular Edema. European Journal of Ophthalmology. 2010;21(6_suppl):10-19.
Staurenghi G, Lai TYY, Mitchell P, et al. Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS. Ophthalmology. 2018;125(6):850-862.
Study of the efficacy and tolerability of intravitreal injections of ranibizumab compared to intravitreal injections of ranibizumab combined with targeted retinal photocoagulation to treat radiation retinopathy (RRR). NCT02222610. Last updated: 11-May-2018. Available at
Schefler AC, Fuller D, Anand R, et al. Ranibizumab for Radiation Retinopathy (RRR): A Prospective, Multicenter Trial of Monthly versus PRN Dosing for Radiation Retinopathy-Related Cystoid Macular Edema. Invest Ophthalmol Vis Sci. 2018;59(9):5987.
Tranos PG, Wickremasinghe SS, Stangos NT, et al. Macular edema. Survey of Ophthalmology. 2004;49(5):470-490.
Scholl S, Augustin A, Loewenstein A, Rizzo S, Kuppermann BD. General Pathophysiology of Macular Edema. European Journal of Ophthalmology. 2010;21(6_suppl):10-19.
Staurenghi G, Lai TYY, Mitchell P, et al. Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS. Ophthalmology. 2018;125(6):850-862.
Reichstein D. Current treatments and preventive strategies for radiation retinopathy. Curr Opin Ophthalmol. 2015;26(3):157-166.
Arevalo JF, Maia M, Garcia-Amaris RA, et al. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology. 2009;116(8):1481-1487.
Staurenghi G, Lai TYY, Mitchell P, et al. Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS. Ophthalmology. 2018;125(6):850-862.
Carricondo PC, Abalem MF, Machado CG, N. K-J. Prophylaxis and treatment of cystoid macular edema after cataract surgery. Rev Bras Oftalmol. 2015;74(2):113-118.
Grzybowski A, Sikorski BL, Ascaso FJ, Huerva V. Pseudophakic cystoid macular edema: update 2016. Clin Interv Aging. 2016;11:1221-1229.
Arevalo JF, Maia M, Garcia-Amaris RA, et al. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology. 2009;116(8):1481-1487.
Staurenghi G, Lai TYY, Mitchell P, et al. Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS. Ophthalmology. 2018;125(6):850-862.
Mitropoulos PG, Chatziralli IP, Peponis VG, Drakos E, Parikakis EA. Intravitreal ranibizumab for the treatment of Irvine-Gass syndrome. Ocul Immunol Inflamm. 2015;23(3):225-231.
Dominguez Fernandez R, Govetto A, Lagoa F, Lorente R. Intravitreal Ranibizumab in the treatment of refractory pseudophakic cystoid macular edema following cataract surgery. Invest Ophthalmol Vis Sci. 2014;55(13):611-611.
Chatziralli I, Maniatea A, Koubouni K, Parikakis E, Mitropoulos P. Intravitreal Ranibizumab for Retinal Arterial Macroaneurysm: Long-Term Results of a Prospective Study. European Journal of Ophthalmology. 2016;27(2):215-219.
Staurenghi G, Lai TYY, Mitchell P, et al. Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS. Ophthalmology. 2018;125(6):850-862.
Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol. 2009;148(2):303-309.e302.
Staurenghi G, Lai TYY, Mitchell P, et al. Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS. Ophthalmology. 2018;125(6):850-862.
Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa. J Ocul Pharmacol Ther. 2009;25(6):545-550.
Shah CR, Brent MH. Treatment of retinitis pigmentosa-related cystoid macular edema with intravitreous ranibizumab. Retin Cases Brief Rep. 2010;4(4):291-293.
Kan E, Yucel OE. Recovery of chronic central serous chorioretinopathy with a single dose of intravitreal ranibizumab injection: A case report. J Exp Clin Med. 2015;32(4):183-186.
Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2015;10.1002/14651858.CD011841.pub2:Pg 9-11.
Kim M, Lee SC, Lee SJ. Intravitreal ranibizumab for acute central serous chorioretinopathy. Ophthalmologica. 2013;229(3):152-157.
Staurenghi G, Lai TYY, Mitchell P, et al. Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS. Ophthalmology. 2018;125(6):850-862.
Bae SH, Heo J, Kim C, et al. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Ophthalmology. 2014;121(2):558-565.
Kim M, Lee SC, Lee SJ. Intravitreal ranibizumab for acute central serous chorioretinopathy. Ophthalmologica. 2013;229(3):152-157.
Finger PT, Chin KJ. Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(2):789-798.
Reichstein D. Current treatments and preventive strategies for radiation retinopathy. Curr Opin Ophthalmol. 2015;26(3):157-166.
Study of the efficacy and tolerability of intravitreal injections of ranibizumab compared to intravitreal injections of ranibizumab combined with targeted retinal photocoagulation to treat radiation retinopathy (RRR). NCT02222610. Last updated: 11-May-2018.
Schefler AC, Fuller D, Anand R, et al. Ranibizumab for Radiation Retinopathy (RRR): A Prospective, Multicenter Trial of Monthly versus PRN Dosing for Radiation Retinopathy-Related Cystoid Macular Edema. Invest Ophthalmol Vis Sci. 2018;59(9):5987.
Aronow ME, Wang J, Lane AM, et al. Macular perfusion status in eyes with choroidal melanoma treated with prophylactic ranibizumab after proton beam irradiation. Invest Ophthalmol Vis Sci. 2018;59(9):4301.
Russo A, Reibaldi M, Avitabile T, et al. Dexamethasone intravitreal implant vs ranibizumab in the treatment of macular edema secondary to brachytherapy for choroidal melanoma. Retina. 2018;38(4):788-794.
Finger PT, Chin KJ. High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy. Eur J Ophthalmol. 2013;23(6):850-856.
Jutley G, Shona OA, Leen RC, et al. Response to ranibizumab following tachyphylaxis to bevacizumab in a patient with radiation maculopathy following stereotactic fractionated radiotherapy for optic nerve meningioma. Arch Ophthalmol. 2012;130(11):1466-1470.
Brand CS. Management of retinal vascular diseases: a patient-centric approach. Eye. 2012;26(S2):S1-S16.
Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study. Ophthalmology. 2011;118(5):831-839.
Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology. 2011;118(4):663-671.
Stoller GL, Kokame GT, Dreyer RF, Shapiro H, Tuomi LL. Patterns of early and delayed visual response to ranibizumab treatment for neovascular age-related macular degeneration. JAMA Ophthalmology. 2016;134(5):545-553.
Eldem BM, Muftuoglu G, Topbas S, et al. A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD. Acta Ophthalmol. 2015;93(6):e458-e464.
Mantel I, Niderprim S-A, Gianniou C, Deli A, Ambresin A. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. British Journal of Ophthalmology. 2014;98(9):1192-1196.
Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181-2192.
Stoller GL, Kokame GT, Dreyer RF, Shapiro H, Tuomi LL. Patterns of early and delayed visual response to ranibizumab treatment for neovascular age-related macular degeneration. JAMA Ophthalmology. 2016;134(5):545-553.
Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181-2192.
Eldem BM, Muftuoglu G, Topbas S, et al. A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD. Acta Ophthalmol. 2015;93(6):e458-e464.
Eldem BM, Muftuoglu G, Topbas S, et al. A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD. Acta Ophthalmol. 2015;93(6):e458-e464.
Mantel I, Niderprim S-A, Gianniou C, Deli A, Ambresin A. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. British Journal of Ophthalmology. 2014;98(9):1192-1196.
Gianniou C, Dirani A, Ferrini W, et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye (Lond). 2015;29(3):342-349.
Wang W, Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments. Int J Mol Sci. 2018;19(6):1816.
Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013; 2013:343560-343560.
Dong F, Yu C, Ding H, Shen L, Lou D. Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment. Medicine (Baltimore). 2016;95(8):e2731.
Wykoff CC, Eichenbaum DA, Roth DB, et al. Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2018;2(10):997-1009.
Boyd K. What is diabetic retinopathy? Available at :https://www.aao.org/eye-health/diseases/what-is-diabetic-retinopathy ; Accessed: 22-Oct-2019.
Gundogan FC, Yolcu U, Akay F, et al. Diabetic Macular Edema. Pak J Med Sci. 2016;32(2):505-510.
Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial JAMA. 2015;314(20):2137-2146.
Gross JG, Glassman AR, Liu D, et al. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2018;136(10):1138-1148.
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
Wykoff CC, Eichenbaum DA, Roth DB, et al. Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2018;2(10):997-1009. 、
Ip MS, Zhang J, Ehrlich JS. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score. Ophthalmology. 2017;124(5):596-603.
Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145-1152.
Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term Effects of Therapy with Ranibizumab on Diabetic Retinopathy Severity and Baseline Risk Factors for Worsening Retinopathy. Ophthalmology. 2015;122(2):367-374.
Sun JK, Wang PW, Taylor S, Haskova Z. Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies. Ophthalmology. 2019;126(5):712-720.
Elman MJ, Qin H, Aiello LP, et al. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: Three-Year Randomized Trial Results. Ophthalmology. 2012;119(11):2312-2318.
Elman MJ, Aiello LP, Beck RW, et al. Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology. 2010;117(6):1064-1077.e1035.
Bressler SB, Odia I, Glassman AR, et al. Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR.net Protocol I 5-Year Report. Retina. 2018;38(10):1896-1904.
Bressler SB, Qin H, Melia M, et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol. 2013;131(8):1033-1040.
Lang GE SA, Spital G et al. Comparison of the efficacy of ranibizumab and panretinal laser photocoagulation in proliferative diabetic retinopathy – 12-months results from the PRIDE Study. Presented at  17th EURETINA Congress. September 7-10,2017, Barcelona, Spain.
Liakopoulos S. Morphological outcomes of the PRIDE study using fluorescein angiography and a modified ETDRS severity scale grading for PDR patients treated with ranibizumab and/or panretinal photocoagulation (PRP). Data presented at 18th EURETINA meeting. Vienna, Austria; September 2018.
Figueira J, Fletcher E, Massin P, et al. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study). Ophthalmology. 2018;125(5):691-700.
Figueira J, Silva R, Henriques J, et al. Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial. Ophthalmologica. 2016;235(1):34-41.
Messias K, Barroso RM, Jorge R, Messias A. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation. Doc Ophthalmol. 2018;137(2):121-129.
Ferraz DA, Vasquez LM, Preti RC, et al. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy. Retina. 2015;35(2):280-287.
Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol. 2011;89(7):e567-572.
Chelala E, Joseph N, Hala ER, et al. Efficacy of intravitreal ranibizumab injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy. Retina. 2018;38(6):1127-1133.
Chae JB, Joe SG, Yang SJ, et al. Effect of combined cataract surgery and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy. Retina. 2014;34(1):149-156.
Dong F, Yu C, Ding H, Shen L, Lou D. Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment. Medicine (Baltimore). 2016;95(8):e2731.
Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013;131(3):283-293.
Chelala E, Joseph N, Hala ER, et al. Efficacy of intravitreal ranibizumab injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy. . Retina. 2018;38(6):1127-1133.
Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84(2):77-82.
Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity. N Engl J Med. 2011;364(7):603-615.
Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. The Lancet. 2019;10.1016/S0140-6736(19)31344-3.
Hellstrom A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013;382(9902):1445-1457.
Hellstrom A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013;382(9902):1445-1457.
Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol. 2009;24(2):77-81.
Liegl R, Hellstrom A, Smith LE. Retinopathy of prematurity: the need for prevention. Eye Brain. 2016; 8:91-102.
Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmologica. 2013;91(1):e74-e75.
Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity. N Engl J Med. 2011;364(7):603-615.
Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. The Lancet. 2019;10.1016/S0140-6736(19)31344-3.
Orozco-Gomez LP, Hernandez-Salazar L, Moguel-Ancheita S, Ramirez-Moreno MA, Morales-Cruz MV. Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience. Cir Cir. 2011;79(3):207-214, 225-232.
Stahl A, Krohne TU, Eter N, et al. Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial. JAMA Pediatrics. 2018;172(3):278-286.
Zhang G, Yang M, Zeng J, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone ii treatment-requiring retinopathy of prematurity. Retina. 2017;37(4):710-717.
Chuluunbat T, Chan RV, Wang NK, et al. Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment. Ophthalmic Surg Lasers Imaging Retina. 2016;47(12):1095-1105.
Aldebasi T, Guma MA, Bashir R, et al. Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity. Med Princ Pract. 2019;10.1159/000500310.
Arambulo O, Dib G, Iturralde J, et al. Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity. Clin Ophthalmol. 2015; 9:2027-20+B370:B38032.
Brand C, Parikh S and Macfadden W. Baseline characteristics of the 30,000 patients enrolled in LUMINOUS™, a real-world study with ranibizumab. Invest Ophthalmol Vis Sci. 2018;59 (9):3902.
Brand C, Mitchell P, Holz FG, et al. Abstract 29: Baseline characteristics of patients enrolled in the real-world LUMINOUS study: data from the final analysis. 17th ESASO Retina Academy; June 29-July 1, 2017; Berlin, Germany. Ophthalmic Res. 2017;58 (Suppl. 1):1-20.
US National Institutes of Health. ClinicalTrials.gov. Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS). NCT01318941.
US National Institutes of Health. ClinicalTrials.gov. Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS). NCT01318941.
Brand C, Mitchell P, Figueroa MS, Lacey S, Macfadden W. Baseline characteristics of 30,000 patients from the final analysis of the real-world LUMINOUS study. Presented at 17th EURETINA Congress, 7‒10 September, 2017, Barcelona, Spain.
Hamilton R, Lai T, Dai H, Macfadden W. Effectiveness and safety of ranibizumab for the treatment of mCNV: 12-month results from the final analysis of the real-world LUMINOUS study. Presented at 17th EURETINA Congress; September 7-10 , 2017; Barcelona, Spain.
Brand C, Parikh S and Macfadden W. Baseline characteristics of the 30,000 patients enrolled in LUMINOUS™, a real-world study with ranibizumab. Invest Ophthalmol Vis Sci. 2018;59 (9):3902.
Sharma S, Parikh S and Macfadden W. Ranibizumab treatment for nAMD in clinical practice: outcomes from the LUMINOUS™ study. Invest Ophthalmol Vis Sci. 2018;59 (9):837. https://iovs.arvojournals.org/article.aspx?articleid=2694238&resultClick=1
Holz FG, Figueroa MS, Bandello F, et al. Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: Results From LUMINOUS, a global real-world study. Retina. 2019;00(00):1-13. https://doi.org/10.1097/IAE.0000000000002670.
Pereira A, Yoganathan P. Treatment patterns of ranibizumab over time in treatment-naïve patients with nAMD: real-world outcomes from LUMINOUS. Poster presented at the American Society of Retina Specialists; July 26-30, 2019; Chicago. USA https://minova.na.novartis.net/Global%20Repository/Lucentis/LO/ASRS%202019__LUMINOUS_Dr.%20Pereira_%20print%20ready.pdf.
Mitchell P, Ziemssen F, Sheidow T, Parikh S, Macfadden W. Visual acuity outcomes in DME patients treated with ranibizumab in a real-life setting: results from the final analysis of the LUMINOUS study. Presented at 17th EURETINA Congress; September 7‒10, 2017; Barcelona, Spain.
Mitchell P, Parikh S and Macfadden W. Effectiveness of ranibizumab for the treatment of patients with diabetic macular edema in a real-world setting: 1- and 2-year results from the LUMINOUS™ study. Invest Ophthalmol Vis Sci. 2018;59 (9):3617.
Pearce I, Tadayoni R, Zangvil E, Macfadden W. Ranibizumab in patients with RVO: results from the final analysis of the real-world LUMINOUS study. Presented at 17th EURETINA Congress; September 7-10, 2017; Barcelona, Spain.
Pearce I, Parikh S and Macfadden W. Real-world outcomes of ranibizumab in patients with retinal vein occlusion from the LUMINOUS™ study. Invest Ophthalmol Vis Sci. 2018;59 (9):2566.
Hamilton R, Lai T, Dai H, Macfadden W. Effectiveness and safety of ranibizumab for the treatment of mCNV: 12-month results from the final analysis of the real-world LUMINOUS study. Presented at 17th EURETINA Congress; September 7-10, 2017; Barcelona, Spain.
Koh A, Lai TYY, Wei WB, et al. Real-world effectiveness and safety of ranibizumab treatment in patients with and without polypoidal choroidal vasculopathy: twelve-month results from the luminous study. Retina. 2019.
Koh A, Lai T, Macfadden W and P. M. Ranibizumab 0.5 mg in treatment-naive asian nAMD patients with and without polypoidal choroidal vasculopathy: 1-year results from the real-world LUMINOUS study. Presented at 33rd Asia Pacific Academy of Ophthalmology (APAO)Congress. 8-11 February, 2018, Hong Kong.,
Supplemental digital content 3. Koh A, Lai TYY, Wei WB, et al. Real-world effectiveness and safety of ranibizumab treatment in patients with and without polypoidal choroidal vasculopathy: twelve-month results from the luminous study. Retina. 2019.
